Table 5.
PyLARC2 immunization protects against P. berghei pre-erythrocytic stage challenge.
| Number of sporozoites used for immunization/challenge | ||||||
|---|---|---|---|---|---|---|
| Mouse strain | Parasite genotype | Route of immunization | Primea | Boost (days after prime)a | Challenge (days after last boost)b | Number of mice protected (days to patency)c |
| BALB/cJ | NA | i.v | – | – | 10,000 P. berghei (30) | 0/3 (4) |
| NA | i.v | Salivary gland extract | Salivary gland extract (30, 60) | 10,000 P. berghei (30) | 0/3 (5) | |
| PyLARC2 | i.v | 50,000 | 50,000 (30, 60) | 10,000 P. berghei (30) | 10/10 | |
aPyLARC2 salivary gland sporozoites were isolated from infected Anopheles stephensi mosquitoes, and mice were i.v. immunized with the listed number of sporozoites. The day intervals after priming are indicated in parentheses.
bMice were challenged intravenously with P. berghei ANKA salivary gland sporozoites. The days after the last boost, when the challenge took place, are indicated in parentheses.
cThe number of protected mice per total mice challenged. The days to patency are indicated in parentheses. Protection was considered complete if mice remained blood stage negative in Giemsa-stained thin blood smear for 21 days after challenge.